Jump to content
Powered by

Amedrix GmbH - New investment paves the way for own production operations

The High-Tech Gründerfonds (HTGF) and Life Science Fonds Esslingen are jointly investing a total of 700,000 EUR in Amedrix GmbH, which was founded in January 2009. The Esslingen-based company develops innovative, acellular medical products based on animal collagen for wound regeneration and the reconstruction of degenerated soft tissue, for example. The new investment means that necessary steps can be taken to gain approval for first medical products and to set up the company's own production operations.

Amedrix GmbH develops and produces acellular implants based on a collagen type I matrix as medical products for various human and veterinarian purposes. The main advan-tage of these implants with regard to their intended application is how production can be varied concerning size, form and consistency. Furthermore, the collagen matrices are distinguished by excellent biocompatibility. In the body, the implants are settled by the patient’s own cells which proliferate and assimilate their specific synthesis activity. Com-pared with cell-settled products already available on the market, this has the benefit that additional and expensive operations for cell-withdrawal are no longer necessary and long waiting periods for patients can be avoided. Amedrix GmbH has set up the technology for collagen and implant production and has tested first prototypes for functionality and bio-compatibility.

Dr. Thomas Graeve © Amedrix GmbH

„The main factors for the success of such products are improved medical options", comments Dr. Thomas Graeve, founder and managing director of Amedrix GmbH. „The quality of patients' care improves with the quality of medical products and their mode of application; minimally invasive operation methods are a good example to illustrate this". Costs for health insurance companies could be lowered significantly by using medical products in the field of regenerative medicine. „As this means that follow-up costs after especially complex treatments can be kept down, we do not expect to counter any resistance", explains Dr. Thomas Graeve convincingly.

The new financing now enables the company to take the necessary steps to obtain approval for its first products and then to set up production. Dr. Graeve is aiming at building up and developing a really strong business in the region with the widest possible spectrum of different medical implants.

Dr. Michael Nettersheim, Investment Manager of High-Tech Gründerfonds Management GmbH is convinced that „Amedrix hits the bull's eye on today's market with its close-to-market medical products. By reducing the number of necessary surgical interventions, Amedrix products are substantially cheaper in comparison to available products and a lot more pleasant for patients".

Stephan Reichstein, manager of the Life Science Fonds Esslingen, is in complete agreement: „This technology really convinces Life Science Fonds Esslingen. As urban business developers, we set great value not only on providing space but also the financial capital needed for the development of such a promising company as Amedrix GmbH. Investing in this company is an investment in the business location of Esslingen".

This view is echoed entirely by Managing Director of BioRegio STERN Management GmbH Dr. Klaus Eichenberg, who originally put Amedrix GmbH into contact with High-Tech Gründerfonds Management GmbH: "Amedrix GmbH is a key partner in our REGiNA project, which has the goal of promoting a User Centre for Regenerative Medicine. This investment reinforces our commitment to the Neckar-Alb and Stuttgart health region, and will ultimately bring great benefits for patients."

Further Information:
Amedrix GmbH
Dr. Thomas Graeve (Geschäftsführer)
Life Science Center Esslingen, Schelztorstraße 54-56
73728 Esslingen
Tel.: 0711-93341410
Mail: info(at)amedrix.de

Website address: https://www.gesundheitsindustrie-bw.de/en/article/press-release/amedrix-gmbh-new-investment-paves-the-way-for-own-production-operations